Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.-MedSci.cn

Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.

Koca, E; Niravath, PA; Ensor, J; Patel, TA; Li, XX; Hemati, P; Wong, H; Qian, W; Boone, T; Zhao, J; Ramshesh, PV; Cohen, AL; Murthy, A; Nair, S; Darcourt, JG; Belcheva, A; Kaklamani, VG; Chang, JCN

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务